retatrutide nash trial What GLP‑3 Really Is: Triple‑Receptor Drug retatrutide nonalcoholic fatty liver disease

Tirzepatide (marketed as Zepbound for weight management and Mounjaro for type 2 diabetes in the UK) is a dual GIP/GLP-1 receptor agonist that has shown similar side effect profiles in clinical trials, including reports of dizziness

Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study

As the most recently developed compound in the GLP-1 agonist research class, retatrutide represents a frontier area of metabolic research with growing interest from the scientific community

For additional product-specific information on agents from the GLP-1 RA class, please refer to the companion lesson titled: An Overview of GLP-1 RAs: What Every Pharmacist Should Know. PUTTING IT ALL TOGETHER: CASE REVIEW AND DISCUSSION Case scenario JM is a 65-year-old man with T2D of 8 years duration

Wegovy is also used to lower the risk of cardiovascular problems, and to treat a serious liver condition called MASH

Weight maintenance is the hardest part, however, and exercise has been shown to prevent weight regain after discontinued use of the drug